Larimar Reports Positive Initial Data From Long-term OLE Study Of Nomlabofusp In Friedreich's Ataxia

(RTTNews) - Larimar Therapeutics, Inc. (LRMR), Monday announced positive initial data from the long-term open label extension (OLE) study of nomlabofusp in participants with Friedreich's Ataxia.

Friedreich's ataxia is a genetic, progressive, neurodegenerative disorder.

Data from the OLE study showed that treatment with nomlabofusp raised frataxin levels in participants. Friedreich's ataxia is caused by frataxin deficiency, and increase in frataxin levels may lead to the slowing of progression of the disease.

The company added that it remains on track to initiate a registrational study of nomlabofusp in mid-2025. It plans to submit Biologics License Application (BLA) in the second half of 2025.